- Home
- CMMB vs AMS Comparison
CMMB vs AMS Comparison
Compare CMMB & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- AMS
- Stock Information
- Founded
- CMMB 2004
- AMS 1980
- Country
- CMMB Israel
- AMS United States
- Employees
- CMMB N/A
- AMS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- AMS Medical Specialities
- Sector
- CMMB Health Care
- AMS Health Care
- Exchange
- CMMB Nasdaq
- AMS Nasdaq
- Market Cap
- CMMB 22.0M
- AMS 18.3M
- IPO Year
- CMMB N/A
- AMS N/A
- Fundamental
- Price
- CMMB $1.13
- AMS $2.41
- Analyst Decision
- CMMB Strong Buy
- AMS
- Analyst Count
- CMMB 2
- AMS 0
- Target Price
- CMMB $8.50
- AMS N/A
- AVG Volume (30 Days)
- CMMB 187.2K
- AMS 17.1K
- Earning Date
- CMMB 08-20-2025
- AMS 08-13-2025
- Dividend Yield
- CMMB N/A
- AMS N/A
- EPS Growth
- CMMB N/A
- AMS 151.01
- EPS
- CMMB N/A
- AMS 0.21
- Revenue
- CMMB N/A
- AMS $29,236,000.00
- Revenue This Year
- CMMB N/A
- AMS $23.63
- Revenue Next Year
- CMMB N/A
- AMS N/A
- P/E Ratio
- CMMB N/A
- AMS $11.35
- Revenue Growth
- CMMB N/A
- AMS 35.25
- 52 Week Low
- CMMB $0.87
- AMS $2.27
- 52 Week High
- CMMB $2.55
- AMS $4.60
- Technical
- Relative Strength Index (RSI)
- CMMB 42.55
- AMS 46.24
- Support Level
- CMMB $1.17
- AMS $2.39
- Resistance Level
- CMMB $1.23
- AMS $2.49
- Average True Range (ATR)
- CMMB 0.05
- AMS 0.13
- MACD
- CMMB 0.00
- AMS 0.00
- Stochastic Oscillator
- CMMB 34.11
- AMS 18.67
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.